FDA Approves First Generic Naloxone Nasal Spray
Unlike injectable versions, naloxone nasal spray may be administered outside a health care setting by anyone, regardless of medical training.
Read More
For Pregnant Smokers, Early Quitting Linked to Lower Preterm Birth Risk
For expectant parents who smoke, quitting before pregnancy or as early as possible during pregnancy was associated with a reduced risk of preterm birth.
STR1VE Trial in SMA1 Demonstrates Positive Interim Results
As of September 2018, 95% of children treated with Zolgensma were alive and did not require permanent ventilation.
Statins Safe for Patients with Rheumatoid Arthritis
The study also found that the overall rate of cardiovascular events was low in the study population, indicating that statins aren’t required for all RA patients.
FDA Accepts NDA for Riluzole Oral Film for ALS Treatment
Riluzole oral film (Exservan) was developed as an option for patients with ALS who have difficulty swallowing medication.
USPSTF: Inconclusive Evidence for Lead Screening in Asymptomatic Children
A task force found insufficient evidence on the benefits and harms of screening for lead in asymptomatic children and pregnant persons.
Facecards Help Patients Recognize Their Physicians
Hospitalized patients were significantly more likely to recognize their physician when they had received a facecard with the doctor’s name and photo.
Marijuana Users Require More Sedatives, Preliminary Study Reports
A small study in Colorado reported that regular marijuana users require significantly greater amounts of sedatives for endoscopic procedures.
Canagliflozin Reduces Risk of End-Stage Kidney Disease in CREDENCE Study
The CREDENCE study of canagliflozin in adults with chronic kidney disease and type 2 diabetes met its primary endpoint as well as cardiovascular endpoints.
Rapid Initiation of Symtuza for HIV Treatment Shows Promise
After initiating treatment with Symtuza within 2 weeks of HIV diagnosis, 84% of patients achieved undetectable viral loads at 48 weeks.
Pediatric Telemedicine Associated with Higher Antibiotic Prescribing
Additionally, guideline adherence in antibiotic prescribing was lower for telemedicine visits than in primary care or urgent care settings.
Long-acting Aristada, Invega Sustenna Comparable for Schizophrenia
Both long-acting injectable treatments produced statistically significant and clinically meaningful improvements.
FDA Clears Radiofrequency Ablation Device
The SIRA RFA Electrosurgical Device is used in electrosurgery for intraoperative coagulation and soft tissue ablation.
FDA Approves HIV Combo Treatment Dolutegravir/Lamivudine
Dovato is a 2-drug regimen approved for treatment-naïve adult patients with HIV infection.
Racial Disparities in Cardiovascular Care Persist for Postmenopausal Women
Investigators have found that despite improvements in women’s cardiovascular health care, black women still face disparities in care compared to white and Hispanic women.
Robert Bober, MD: Results of the Optimal Hospital Innovations
By applying research-supported practices, Optimal Hospital has increased patient sleep, improved HCAHPS scores, and decreased length of stay and readmissions.
Long-term Success for Extended-Release Buprenorphine Injection
An extended-release, subcutaneous injection form of buprenorphine (Sublocade) demonstrated long-term efficacy and safety results.
Robert Bober, MD: Empowering Patients During a Hospital Stay
Patients in the Optimal Hospital wing are given iPads that let them access their medical records, see their care team, and view the schedule of their upcoming tests.
Robert Bober, MD: Designing a Better Hospital Room
New features include wireless vital monitors, red lighting for nighttime, and surfaces and linens infused with antimicrobial copper.
Robert Bober, MD: What is Optimal Hospital?
Ochsner Medical Center's innovative Optimal Hospital initiative has sought to reduce hospital-acquired infections, length of stay, and readmissions.
FDA Approves Cerene Cryotherapy Device for Heavy Menstrual Bleeding
Endometrial ablation with the Cerene Device does not require general anesthesia and can be performed in a gynecologist’s office.
FDA Issues CRL for Rizaport Acute Migraine Treatment
The Complete Response Letter highlights issues in the Chemistry, Manufacturing, and Controls section of the application.
FDA Approves Tegaserod Reintroduction for IBS with Constipation
Originally approved in 2002, tegaserod (Zelnorm) was withdrawn in 2007 due to potential safety concerns.
sNDA Submitted for Icosapent Ethyl for MACE Reduction Indication
The application to the FDA for icosapent ethyl seeks a new indication to reduce the risk of major adverse cardiovascular events.
FDA Approves Certolizumab for Non-radiographic Axial Spondyloarthritis
Certolizumab pegol (Cimzia) is the first FDA-approved treatment for the condition.
SPN-812 Reduces ADHD Symptoms in Phase 3 Study
A fourth phase 3 study of investigational drug SPN-812 demonstrated a significant decrease in ADHD-RS-5 scores compared to placebo.
Canagliflozin sNDA Submitted for Chronic Kidney Disease with Diabetes
The canagliflozin (Invokana) application seeks a new indication to treat chronic kidney disease in patients with type 2 diabetes.
Lack of Guidance, Side Effects Keep Patients from Taking Statins
A study of patients recommended for statin therapy under ACC/AHA guidelines, but not taking any, found that 59.2% reported never being offered a statin.
Air Pollution Linked to Adolescent Psychotic Experiences
Higher exposure to air pollutants, especially NO2 and NOx, was found to be associated with greater odds of psychotic experiences in adolescents.
FDA Designates PRM-151 Breakthrough Therapy for Idiopathic Pulmonary Fibrosis
The investigational anti-fibrotic immunomodulator is being investigated for respiratory, oncology, hepatology, and nephrology indications.